Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Nuvation Bio Inc's Business Segments
Nuvation Bio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
6
Largest Segment
US
Total Revenue
$ 32
Countrys Reported
3
Revenue Share by Reportable Segment - FY
- US0%
- License0%
- Product0%
- CN41.6%
- Research And Development Service Revenue0.6%
- Product Revenue0.3%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 101 | - |
| License | $ 73 | - |
| Product | $ 42 | - |
3 more segments available
Sign in to unlock the full Nuvation Bio Inc dataset.
Revenue Share by Country - FY
- US93%
- CN6.2%
- JP0.8%
Revenue by Geographic Country - FY
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 77 | 93% |
| CN | $ 5 | 6.2% |
| JP | $ 1 | 0.8% |
Revenue by Product & Service Category - FY
- License77.8%
- Product22.2%
- Product Revenue22.2%
- Royalty Revenue1.7%
- Research And Development Service Revenue0.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 65 | 77.8% |
| Product | $ 19 | 22.2% |
| Product Revenue | $ 19 | 22.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
2 more categories available
Sign in to unlock the full Nuvation Bio Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- US0%
- License0%
- Product0%
- CN41.6%
- Research And Development Service Revenue0.6%
- Product Revenue0.3%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 101 | - |
| License | $ 73 | - |
| Product | $ 42 | - |
3 more segments available
Sign in to unlock the full Nuvation Bio Inc dataset.
Description of Nuvation Bio Inc
Nuvation Bio Inc. is a biopharmaceutical company that specializes in the research, development, and delivery of innovative therapies for the treatment of chronic diseases. The company's mission is to improve the lives of patients by creating transformative medicines that address unmet medical needs.
Nuvation Bio's primary focus is on the development of a new class of drugs known as engineered decoy receptors. These drugs are designed to target the root cause of chronic diseases by neutralizing specific proteins in the body that contribute to disease progression. By doing so, the company hopes to provide patients with more effective and durable treatments that have fewer side effects than traditional drugs.
The company was founded in 2018 by several renowned scientists and biotech entrepreneurs, including Dr. George Gilliland and Dr. Robert Tjian. Dr. Gilliland is a leading expert in protein engineering and has led the development of several successful biotech companies, while Dr. Tjian is a renowned biochemist and former president of the Howard Hughes Medical Institute.
Since its inception, Nuvation Bio has made significant progress in the development of its platform technology and drug candidates. The company recently announced promising preclinical data for its lead program, NB-101, which targets a protein involved in the development of fibrotic diseases.
In addition to its internal drug development efforts, Nuvation Bio has established several partnerships and collaborations with other leading biopharmaceutical companies. These relationships provide the company with access to new technologies and expertise, which it can leverage to accelerate the development of its pipeline.
Overall, Nuvation Bio Inc. is an innovative biopharmaceutical company that is well-positioned to make a significant impact in the field of chronic disease treatment. The company's platform technology and pipeline of drug candidates hold great promise for improving the lives of millions of patients worldwide.
Nuvation Bio's primary focus is on the development of a new class of drugs known as engineered decoy receptors. These drugs are designed to target the root cause of chronic diseases by neutralizing specific proteins in the body that contribute to disease progression. By doing so, the company hopes to provide patients with more effective and durable treatments that have fewer side effects than traditional drugs.
The company was founded in 2018 by several renowned scientists and biotech entrepreneurs, including Dr. George Gilliland and Dr. Robert Tjian. Dr. Gilliland is a leading expert in protein engineering and has led the development of several successful biotech companies, while Dr. Tjian is a renowned biochemist and former president of the Howard Hughes Medical Institute.
Since its inception, Nuvation Bio has made significant progress in the development of its platform technology and drug candidates. The company recently announced promising preclinical data for its lead program, NB-101, which targets a protein involved in the development of fibrotic diseases.
In addition to its internal drug development efforts, Nuvation Bio has established several partnerships and collaborations with other leading biopharmaceutical companies. These relationships provide the company with access to new technologies and expertise, which it can leverage to accelerate the development of its pipeline.
Overall, Nuvation Bio Inc. is an innovative biopharmaceutical company that is well-positioned to make a significant impact in the field of chronic disease treatment. The company's platform technology and pipeline of drug candidates hold great promise for improving the lives of millions of patients worldwide.
Nuvation Bio Inc is a biotechnology company focused on creating novel, targeted biologic therapies aimed at addressing significant unmet medical needs in areas such as cancer and autoimmune disorders. Their approach integrates advanced technologies, including genomics, proteomics, and machine learning, to support their product development and therapeutic innovation.
Segments
Nuvation Bio Inc categorizes its offerings into distinct segments that reflect its multifaceted approach to biotechnology. These segments include:
1. Therapeutic Products: This segment comprises biologic therapies that are specifically designed to treat various diseases, particularly those related to cancer and autoimmune disorders. Utilizing proprietary technology platforms, Nuvation Bio leverages cutting-edge methodologies to identify drug targets and develop potent drug candidates. The therapeutic products aim not only to address the efficacy of treatments but also to minimize side effects through precise targeting.
2. Diagnostics: Nuvation Bio’s diagnostics segment focuses on the development of diagnostic tools aimed at detecting biomarkers and disease signatures. The goal here is to enable the early diagnosis and personalized treatment strategies for patients. Using advanced technologies like DNA sequencing, transcriptomics, and proteomics, Nuvation Bio aims to delineate the unique genetic and molecular characteristics of diseases, facilitating more effective disease management.
Products
Nuvation Bio Inc offers a range of innovative products, which include:
1. NUV-422: This monoclonal antibody therapeutic is developed to target solid tumors. It specifically focuses on a novel tumor antigen that is often overexpressed on the surfaces of cancerous cells. Pre-clinical studies have shown substantial anti-tumor activity, illustrating its potential efficacy as a cancer treatment.
2. NUV-202: Aimed at treating autoimmune disorders, NUV-202 is another monoclonal antibody therapeutic. It targets a critical immune regulatory protein that is often dysfunctional in conditions like rheumatoid arthritis and psoriasis. Preliminary studies indicate that this product exhibits strong immune-modulatory effects, making it a promising candidate for managing autoimmune conditions.
3. NUV-Dx: This diagnostic platform utilizes RNA sequencing technology to pinpoint disease-specific biomarkers and signatures. NUV-Dx can identify various genetic alterations, including mutations and fusions, along with gene expression profiles and immune cell presence in tissues. This platform not only supports the therapeutic side of the company but also plays a critical role in developing companion diagnostics for Nuvation Bios therapies.
Services
Nuvation Bio Inc provides several essential services aimed at enhancing drug development and improving patient outcomes:
1. Drug Discovery: Leveraging its proprietary technology platform, Nuvation Bio offers drug discovery services to aid in the development of novel biologic therapies. This includes the capacity to screen extensive libraries of compounds, optimize potential drug candidates, and conduct thorough pre-clinical studies to assess both efficacy and safety profiles.
2. Biomarker Discovery: The company provides biomarker discovery services that utilize advanced genomic and proteomic techniques to identify disease-specific biomarkers. These biomarkers are crucial for the development of companion diagnostics tailored to Nuvation Bio’s therapeutic products, as well as for patient stratification during clinical trials.
3. Companion Diagnostics: Nuvation Bio is involved in the development and validation of companion diagnostics, which are critical for predicting patient responses to their therapeutic products. These diagnostic tests assist clinicians in making informed decisions about treatment options, ensuring better alignment between specific therapies and patient needs.
Conclusion
Nuvation Bio Inc stands at the forefront of biotechnology, focusing on innovative biopharmaceutical solutions. Through a blend of targeted therapeutic products, advanced diagnostic tools, and supportive services, the company seeks to transform the treatment landscape for patients with cancer and autoimmune diseases. This comprehensive suite of offerings underscores Nuvation Bios commitment to addressing some of the most pressing healthcare challenges of our time.
Segments
Nuvation Bio Inc categorizes its offerings into distinct segments that reflect its multifaceted approach to biotechnology. These segments include:
1. Therapeutic Products: This segment comprises biologic therapies that are specifically designed to treat various diseases, particularly those related to cancer and autoimmune disorders. Utilizing proprietary technology platforms, Nuvation Bio leverages cutting-edge methodologies to identify drug targets and develop potent drug candidates. The therapeutic products aim not only to address the efficacy of treatments but also to minimize side effects through precise targeting.
2. Diagnostics: Nuvation Bio’s diagnostics segment focuses on the development of diagnostic tools aimed at detecting biomarkers and disease signatures. The goal here is to enable the early diagnosis and personalized treatment strategies for patients. Using advanced technologies like DNA sequencing, transcriptomics, and proteomics, Nuvation Bio aims to delineate the unique genetic and molecular characteristics of diseases, facilitating more effective disease management.
Products
Nuvation Bio Inc offers a range of innovative products, which include:
1. NUV-422: This monoclonal antibody therapeutic is developed to target solid tumors. It specifically focuses on a novel tumor antigen that is often overexpressed on the surfaces of cancerous cells. Pre-clinical studies have shown substantial anti-tumor activity, illustrating its potential efficacy as a cancer treatment.
2. NUV-202: Aimed at treating autoimmune disorders, NUV-202 is another monoclonal antibody therapeutic. It targets a critical immune regulatory protein that is often dysfunctional in conditions like rheumatoid arthritis and psoriasis. Preliminary studies indicate that this product exhibits strong immune-modulatory effects, making it a promising candidate for managing autoimmune conditions.
3. NUV-Dx: This diagnostic platform utilizes RNA sequencing technology to pinpoint disease-specific biomarkers and signatures. NUV-Dx can identify various genetic alterations, including mutations and fusions, along with gene expression profiles and immune cell presence in tissues. This platform not only supports the therapeutic side of the company but also plays a critical role in developing companion diagnostics for Nuvation Bios therapies.
Services
Nuvation Bio Inc provides several essential services aimed at enhancing drug development and improving patient outcomes:
1. Drug Discovery: Leveraging its proprietary technology platform, Nuvation Bio offers drug discovery services to aid in the development of novel biologic therapies. This includes the capacity to screen extensive libraries of compounds, optimize potential drug candidates, and conduct thorough pre-clinical studies to assess both efficacy and safety profiles.
2. Biomarker Discovery: The company provides biomarker discovery services that utilize advanced genomic and proteomic techniques to identify disease-specific biomarkers. These biomarkers are crucial for the development of companion diagnostics tailored to Nuvation Bio’s therapeutic products, as well as for patient stratification during clinical trials.
3. Companion Diagnostics: Nuvation Bio is involved in the development and validation of companion diagnostics, which are critical for predicting patient responses to their therapeutic products. These diagnostic tests assist clinicians in making informed decisions about treatment options, ensuring better alignment between specific therapies and patient needs.
Conclusion
Nuvation Bio Inc stands at the forefront of biotechnology, focusing on innovative biopharmaceutical solutions. Through a blend of targeted therapeutic products, advanced diagnostic tools, and supportive services, the company seeks to transform the treatment landscape for patients with cancer and autoimmune diseases. This comprehensive suite of offerings underscores Nuvation Bios commitment to addressing some of the most pressing healthcare challenges of our time.